Chanadda Chinthammit, PhD

Real-World evidence research

Pharmaceutical Sciences
Pharmaceutical Economics, Policy and Outcome
Research Scientist at Eli Lilly
Dissertation Title: 
Impact of Geographic Variation, Disability, Socioeconomic Status and Risk Adjustment on High-Risk Medication Use among Elderly Medicare Beneficiaries
Year Enrolled: 

BS Pharmaceutical Sciences (2008), Chulalongkorn University

Research Interests: 

Objectives: This study estimated the cost-effectiveness of pharmacist discharge counseling on medication-related morbidity in both the high-risk elderly and general US population.

Methods: A cost-effectiveness decision analytic model was developed using a health care system perspective based on published clinical trials. Costs included direct medical costs, and the effectiveness unit was patients discharged without suffering a subsequent adverse drug event. A systematic review of published studies was conducted to estimate variable probabilities in the cost-effectiveness model. To test the robustness of the results, a second-order probabilistic sensitivity analysis (Monte Carlo simulation) was used to run 10 000 cases through the model sampling across all distributions simultaneously.
Results: Pharmacist counseling at hospital discharge provided a small, but statistically significant, clinical improvement at a similar overall cost. Pharmacist counseling was cost saving in approximately 48% of scenarios and in the remaining scenarios had a low willingness-to-pay threshold for all scenarios being cost-effective. In addition, discharge counseling was more cost-effective in the high-risk elderly population compared to the general population.
Conclusion: This cost-effectiveness analysis suggests that discharge counseling by pharmacists is quite cost-effective and estimated to be cost saving in over 48% of cases. High-risk elderly patients appear to especially benefit from these pharmacist services.
Honors and Achievements: 
  • 2018        Semi-finalist for a Research Poster Presentation Award, The International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia Pacific conference, Tokyo, Japan,
  • 2017        First Place Award of Best Podium Presentation, Western Pharmacoeconomics and Outcomes Research Conference (WPC) 2017, Albuquerque, New Mexico, USA
  • 2017        Academic Excellence in the Health Pharmaceutical Outcomes, University of Arizona College of Pharmacy, Tucson, AZ, USA
  • 2016        William & Betty Milleson Fink Graduate Scholarship, University of Arizona College of Pharmacy, Tucson, AZ, USA
  • 2014        Certificate of Appreciation in Recognition of Service as a Project Advisor, University of Arizona College of Pharmacy, Tucson, AZ, USA
  • 2014        Silver Medal Winning Abstract, Academy of Managed Care Pharmacy (AMCP) 2014 Nexus Meeting, Boston, MA, USA

Professional Leadership & Membership

  • The Rho Chi Pharmacy Honor Society, University of Arizona College of Pharmacy

     2016-Present      Lifetime member

  • International Society for Pharmacoeconomics & Outcomes Research (ISPOR)

    2017-2018       Member, ISPOR Thailand Chatpter

    2012-Present   Member, national ISPOR

    2013-2015      Treasurer, Student Chapter, University of Arizona

  • The United States-Thai Pharmacy School Consortium

     2016-2017     Member, Research working group

  • International Society for Quality of Life Research (ISOQOL)

     2015-2016     Member, Mixed Methods and Psychometric Special Interest Group (SIG)

     2015-2016     Member

  • Pharmacy Quality Alliance (PQA)

     2015-2016    Member, Stakeholder Advisory Panel

  1. Chinthammit C, Harrington A, Wild A, Werner S, Boesen K, Taylor AM, Warholak TL. "Retrospective Review of Exceptions for Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) Recommendations for a Diabetic Medicare Population. Journal of Managed Care & Specialty Pharmacy. In press.
  2. Chinthammit C, Rupp MT, Armstrong EP, Modisett T, Snead RP, Warholak TL. Evaluation of a guided continuous quality improvement program in community pharmacies. Journal of Pharmaceutical Policy and Practice. 2017 Dec 1;10(1):26.
  3. Sakthong P, Chinthammit C, Sukarnjanaset P, Sonsa-ardjit N, Munpan W. Psychometric properties of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL). Value in Health Regional Issues. 2017 May 31;12:41-9.
  4. Lo-Ciganic WH, Floden L, Lee JK, Ashbeck EL, Zhou L, Chinthammit C, Purdy AW, Kwoh CK. Analgesic use and risk of recurrent falls in participants with or at risk of knee osteoarthritis: data from the Osteoarthritis Initiative. Osteoarthritis and Cartilage. 2017 Apr 4.
  5. Chinthammit C, Coull BM, Nimworapan M, Bhattacharjee S. Co-occurring Chronic Conditions and Economic Burden among Stroke Survivors in the United States: A Propensity Score-Matched Analysis. Journal of Stroke and Cerebrovascular Diseases. 2017 Feb 28;26(2):393-402.
  6. Nerapusee O, Chinthammit C, Romyen C, Pangjunhom M, Malone DC, Sakulbumrungsil R. Long-acting injectable antipsychotics in patients with schizophrenia: systematic review and mixed treatment meta-analysis. Asian Biomed. 2016 Mar 21;9(6):741.
  7. Chinthammit C, Armstrong EP, Boesen K, Martin R, Taylor AM, Warholak TL. Cost-Effectiveness of Comprehensive Medication Reviews Versus Noncomprehensive Medication Review Interventions and Subsequent Successful Medication Changes in a Medicare Part D Population. Journal of Managed Care & Specialty Pharmacy. 2015 May;21(5):381-9.
  8. Euasobhon P, Chaudakshetrin P, Rushatamukayanunt P, Mandee S, Chinthammit C. Incidence and Treatment Strategies of Neuropathic Pain: The Tertiary Care Setting’s Experience. Siriraj Medical Journal. 2013:123-7.
  9. Chinthammit C, Armstrong EP, Warholak TL. A cost-effectiveness evaluation of hospital discharge counseling by pharmacists. Journal of Pharmacy Practice. 2012 Apr;25(2):201-8.
Career Type: